Molineaux CJ[au] - Search Results

Year	Number of Results
1978	1
1980	1
1982	3
1983	2
1984	2
1985	4
1986	1
1988	2
1989	1
1990	1
1991	4
1992	1
1993	1
1994	2
2007	1
2009	1
2011	1
2012	1
2022	0

1

Endopeptidase-24.15 in rat hypothalamic/pituitary/gonadal axis.

Pierotti AR, Lasdun A, Ayala JM, Roberts JL, Molineaux CJ. Pierotti AR, et al. Among authors: molineaux cj. Mol Cell Endocrinol. 1991 Apr;76(1-3):95-103. doi: 10.1016/0303-7207(91)90264-s. Mol Cell Endocrinol. 1991. PMID: 1820981

2

Protection from mutagenic effects of antischistosomal and other drugs.

Bueding E, Batzinger RP, Cha YN, Talalay P, Molineaux CJ. Bueding E, et al. Among authors: molineaux cj. Pharmacol Rev. 1978 Dec;30(4):547-54. Pharmacol Rev. 1978. PMID: 392546 Review. No abstract available.

3

Substrate-related potent inhibitors of brain metalloendopeptidase.

Orlowski M, Michaud C, Molineaux CJ. Orlowski M, et al. Among authors: molineaux cj. Biochemistry. 1988 Jan 26;27(2):597-602. doi: 10.1021/bi00402a015. Biochemistry. 1988. PMID: 3162384

4

Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.

Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ. Yang J, et al. Among authors: molineaux cj. Drug Metab Dispos. 2011 Oct;39(10):1873-82. doi: 10.1124/dmd.111.039164. Epub 2011 Jul 13. Drug Metab Dispos. 2011. PMID: 21752943

5

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK. Demo SD, et al. Among authors: molineaux cj. Cancer Res. 2007 Jul 1;67(13):6383-91. doi: 10.1158/0008-5472.CAN-06-4086. Cancer Res. 2007. PMID: 17616698 Free article.

6

Antinociceptive properties of inhibitors of endopeptidase 24.15.

Kest B, Orlowski M, Molineaux CJ, Bodnar RJ. Kest B, et al. Among authors: molineaux cj. Int J Neurosci. 1991 Jan-Feb;56(1-4):141-9. doi: 10.3109/00207459108985410. Int J Neurosci. 1991. PMID: 1938129

7

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL, Wong A, Kunkel LA, Molineaux CJ, Goy A. Alsina M, et al. Among authors: molineaux cj. Clin Cancer Res. 2012 Sep 1;18(17):4830-40. doi: 10.1158/1078-0432.CCR-11-3007. Epub 2012 Jul 3. Clin Cancer Res. 2012. PMID: 22761464 Free article. Clinical Trial.

8

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ. O'Connor OA, et al. Among authors: molineaux cj. Clin Cancer Res. 2009 Nov 15;15(22):7085-91. doi: 10.1158/1078-0432.CCR-09-0822. Epub 2009 Nov 10. Clin Cancer Res. 2009. PMID: 19903785 Free PMC article. Clinical Trial.

9

Subcellular localization of immunoreactive dynorphin and vasopressin in rat pituitary and hypothalamus.

Molineaux CJ, Cox BM. Molineaux CJ, et al. Life Sci. 1982 Oct 18-25;31(16-17):1765-8. doi: 10.1016/0024-3205(82)90205-3. Life Sci. 1982. PMID: 6130435

10

Endogenous opioid immunoreactivity in rat spinal cord following traumatic injury.

Faden AI, Molineaux CJ, Rosenberger JG, Jacobs TP, Cox BM. Faden AI, et al. Among authors: molineaux cj. Ann Neurol. 1985 Apr;17(4):386-90. doi: 10.1002/ana.410170414. Ann Neurol. 1985. PMID: 2860844

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results